Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome

May 29, 2022 updated by: Charlotte von der Lippe, Oslo University Hospital

Characterizing the Genotype, Phenotype, Health Issues, and Quality of Life in Adults With Bardet-Biedl Syndrome

Bardet-Biedl syndrome (BBS; OMIN #209900) is a rare genetic disorder characterized by six core features: rod-cone dystrophy (retinitis pigmentosa), polydactyly, obesity, genital anomalies, renal anomalies, and learning difficulties. This study aims to contribute to genetic and medical knowledge of BBS, and to provide information on quality of life in adults with BBS and their close relatives. Participants will undergo medical assessments (ocular, oral, and physical examinations) and self-reporting of quality of life, diet, cognitive and emotional symptoms. There are some known genotype-phenotype associations in BBS and participants will be offered genetic testing. It is important to map both genotype and associated phenotype in order to provide optimal treatment and follow-up. Individuals with BBS, age 16 years or older, will be invited to participate. The investigators expect to enroll at least 25 male and female adults with BBS and 15 of their parents to participate in qualitative interviews. These interviews will investigate parents' experiences having a child with BBS, satisfaction with health care services, experience with social and family life, and psychological health.

Study Overview

Status

Enrolling by invitation

Intervention / Treatment

Detailed Description

Improved care for adults with BBS living in Norway necessitates increased knowledge of pertinent health-related, emotional, and educational, employment and psychosocial issues. Adults with BBS living in Norway may face new challenges and have unmet healthcare needs. Therefore, the investigators intend to evaluate the adult with BBS as a person with special needs (e.g. need for support systems, lack of social opportunities, and mental health problems) and long-term challenges.This project will describe the visual, medical, physical, nutritional, and psychological difficulties experienced by people with BBS. The planned multi-disciplinary clinical evaluation in this study can help address the existing knowledge gaps. Relatives who help their loved ones with various activities of daily living may experience reduced quality of life and altered social roles. Therefore, the investigators also want to study the quality of life and psychological status of close relatives. This project might contribute information for new clinical protocols and suggest areas for further research in genetics, healthcare needs and quality of life for people living with BBS.

Study Type

Observational

Enrollment (Anticipated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Oslo, Norway, 0373
        • Oslo University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 80 years (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Individuals with BBS, age 16 years or older

Description

Inclusion Criteria:

Individuals diagnosed with BBS (see below), age 16 years or older. BBS is characterized by six core features : rod-cone dystrophy (retinitis pigmentosa), polydactyly, obesity, genital anomalies, renal anomalies, and learning difficulties.

Additional features include speech delay, developmental delay, diabetes mellitus, dental anomalies, congenital heart disease, brachydactyly (shortening of fingers/toes), ataxia, and anosmia/hyposmia (deficienct sense of smell). A minimum of four of the core features, or three core features and two additional features are required for the clinical diagnosis of BBS.

Exclusion Criteria:

Individuals age < 16 years, current severe illness or known diagnosis of autism.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Medical Outcome Study 36-item Short Form Health Survey (SF-36)
Time Frame: Feb 2022-Dec 2026
Health related quality of life (HRQOL) including measures of Physical and mental HRQOL. The SF-36 is a generic quality of life scale which has been validated in Norway. SF-36 evaluates eight domains of health: physical functioning, role limitation due to physical problems, bodily pain, general perception of health, social functioning, role limitations due to emotional functioning, vitality and mental health. Items on each scale are summed to yield a score from 0-100. A higher score means better quality of life. A license from Quality Metric is used for scoring (License number QM051240). The eight domains are summarized into physical component summary scores and mental component summary scores.
Feb 2022-Dec 2026
Needs and Provision Complexity Scale
Time Frame: Feb 2022-Dec 2026
Presence of health care needs. This is an interview that evaluates the needs for healthcare and social support services. It has two parts: Part A (Needs) is completed by the clinician to evaluate each patient's need for health and social care; and Part B (Gets) is to evaluate to which these needs are met through the services that have been provided, based on information provided by the patient and a close relative. Each part includes 15 items with a total scoring range of 0-50 covering low and high levels of needs. There are six subscales representing two domains: Health and personal care needs, and Social and support needs. This scale was developed in the UK for neurological conditions and has been translated and used in Norway.
Feb 2022-Dec 2026
Behavioral Rating Inventory of Executive Function- Adult Version
Time Frame: Feb 2022-Dec 2026
Assessing cognitive problems. BRIEF-A is a measure of everyday executive functions using self-reports. It includes 75 items that assess nine aspects of executive functioning symptoms of everyday life. Raw scores are transformed into age-corrected T-scores. Higher T-scores mean better executive function.
Feb 2022-Dec 2026

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short Physical Performance Battery;
Time Frame: Feb 2022-Dec 2026
Assessing physical problems. This is a group of measures that combines the results of the gait speed, chair stand and balance tests. The scores range from 0 (worst performance) to 12 (best performance).It has been used as a predictive tool for possible disability.
Feb 2022-Dec 2026
The Hospital Anxiety and Depression Scale;
Time Frame: Feb 2022-Dec 2026
Assessing anxiety and depression symptoms. This is a generic instrument used to address symptoms of depression and anxiety. The two subscales (anxiety, depression) consist of seven items rated on a four-point scale from 0 (no symptom) to three (severe symptom). A score of >7 on either subscale indicates at least a mild level of depressive or anxiety symptoms. A total HADS score may be used as a global measure of psychological distress. It is widely used in various somatic and psychiatric populations.
Feb 2022-Dec 2026
Three Factor Eating Questionnaire-R21
Time Frame: Feb 2022-Dec 2026
Assessing eating habits. This is a frequently used validated scale that measures three domains of eating behavior (cognitive restraint, uncontrolled eating and emotional eating). The first 20 items are rated on a 4-point Likert scale and the item 21 is answered through an 8-point Likert scale. Scores range from 0-100, with higher scores being indicative of greater restraint eating.
Feb 2022-Dec 2026

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Charlotte von der Lippe, MD, PhD, Oslo University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 1, 2022

Primary Completion (ANTICIPATED)

December 31, 2022

Study Completion (ANTICIPATED)

December 31, 2026

Study Registration Dates

First Submitted

December 22, 2021

First Submitted That Met QC Criteria

May 29, 2022

First Posted (ACTUAL)

June 1, 2022

Study Record Updates

Last Update Posted (ACTUAL)

June 1, 2022

Last Update Submitted That Met QC Criteria

May 29, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Norwegian BBS patients belong to a small group. Access to a limited version of the dataset containing selected variables may be made available on request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bardet-Biedl Syndrome

Clinical Trials on No intervention

3
Subscribe